Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.04.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Xiaolan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laborat…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, St Jude Children's Research Hospital, American Lebanese Syrian Associated Charities.
Abstract (Originalsprache)
Treatment outcomes for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remained poor despite the use of intensive chemotherapy, imatinib or dasatinib, and consolidative allogeneic hematopoietic cell transplantation. Oleverembatinib, a third-generation ABL inhibitor, was found to be highly effective and safe in adults with chronic myeloid leukemia and in some adults with relapsed or refractory Ph+ ALL. We reviewed the efficacy and safety profile of olverembatinib treatment in 6 children with relapsed Ph+ ALL and 1 with T-ALL and ABL class fusion, all of whom had previously received dasatinib or intolerance to dasatinib. The median duration of olverembatinib treatment was 70 days (range: 4-340) and the median cumulative dose was 600 mg (range: 80-3810). Complete remission with negative minimal residual level (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Blood Diseases Center, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospit…
- Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
- Division of Hematology/Oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Departments of Oncology, Global Pediatric Medicine and Pathology, St. Jude Children's Research Hospital, Memphis, TN. Electronic address: Ching-Hon.Pui@STJUDE.ORG.
Förderung
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
- St Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Zhang, J., Liu, F., Liu, T., Zhang, R., Chen, Y., Guo, Y., Fang, Y., Xu, X., Pui, C. H., & Zhu, X. (2023). Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.04.012
Vancouver
Li X, Zhang J, Liu F, Liu T, Zhang R, Chen Y, et al. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.04.012
BibTeX
@article{Li2023,
author = {Li, Xiaolan and Zhang, Jingliao and Liu, Fang and Liu, Tianfeng and Zhang, Ranran and Chen, Yumei and Guo, Ye and Fang, Yongjun and Xu, Xiaojun and Pui, Ching-Hon and Zhu, Xiaofan},
title = {Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.04.012}
}
EUVIMED